Redwood Pharma
Redwood Pharma files for bankruptcy
The reason for the bankruptcy filing is that, despite intensive work in 2024, Redwood Pharma has not found a sound and workable solution for its strained financial situation in the short and medium terms. Unfortunately, under the current circumstances, this work has been fruitless, despite the fact that submission of the application for CE marking of RP501, the company's first-line therapy against dry eyes, was imminent.
The board has today, based on the above, therefore come to the conclusion that the only alternative is to apply for bankruptcy at the Stockholm District Court. The Board of Directors considers this decision to be the least harmful to the Company's creditors and its shareholders.
This disclosure contains information that Redwood Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-07-2024 14:30 CET.
| Datum | 2024-07-28, kl 14:30 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!